Inclusion Criteria:

- Patients must have histologically or cytologically confirmed colorectal cancer which
is recurrent or metastatic, and not amendable to surgical resection or radiation.

- Patients must have measurable disease, defined as at least one lesion that can be
accurately measured in at least one dimension (longest diameter to be recorded) as
>20 mm with conventional techniques or as >10 mm with spiral CT scan. See section
11.2 for the evaluation of measurable disease.

- Patients must have had no previous chemotherapy or treatment with an investigational
agent for recurrent or metastatic disease. Prior chemotherapy in the adjuvant
setting for colorectal cancer is acceptable. Prior surgery or radiotherapy for
recurrent or metastatic disease is acceptable, however, patients must be adequately
recovered from the effects of these treatments. At least 6 weeks must have elapsed
from major surgery and 4 weeks must have elapsed from any radiation therapy.

- Age >18 years. Because no dosing or adverse event data are currently available on
the use of bevacizumab in combination with capecitabine and irinotecan in patients
<18 years of age, children are excluded from this study.

- Estimated life expectancy of greater than 3 months.

- ECOG performance status 0, 1, or 2 (or Karnofsky >60%; see Appendix A).

- Patients must have normal organ and marrow function as defined below:

leukocytes >/= 3,000/mcL absolute neutrophil count >/= 1,500/mcL platelets >/= 100,000/mcL
hemoglobin >/= 90 g/L total bilirubin creatinine clearance >/= 50 mL/min/1.73 m2 for patients with creatinine levels above
institutional normal proteinuria < 2+ on dipstick patients with >/= 2+ proteinuria on
urine dipstick at baseline should undergo a 24-hour urine collection, and must have protein / 24 hours

- Appropriate imaging investigations, including chest X-rays and / or CT/MRI of chest /
abdomen / pelvis or other scans as clinically indicated to document all sites of
disease must be performed within 28 days of study entry.

- The effects of bevacizumab on the developing human fetus at the recommended
therapeutic dose are unknown. For this reason and because antiangiogenic agents as
well as other therapeutic agents used in this trial are known to be teratogenic,
women of child-bearing potential and men must agree to use adequate contraception
(hormonal or barrier method of birth control; abstinence) prior to study entry, for
the duration of study and for a period of four weeks after cessation of study
therapy. Should a woman become pregnant or suspect she is pregnant while
participating in this study, she must inform her treating physician immediately.

- Ability to understand and the willingness to sign a written informed consent
document.

Exclusion Criteria:

- History of other malignancies, except: adequately treated non-melanoma skin cancer,
curatively treated in-situ cancer of the cervix, or other solid malignancies
curatively treated with no evidence of disease for ≥ 5 years.

- Patients may not be receiving any other investigational agents.

- Patients with known metastases in the central nervous system.

- Any condition that does not permit compliance with the study protocol

- Previous history of gastrointestinal perforation, uncontrolled gastrointestinal
bleeding, uncontrolled thromboembolism

- Presence of uncontrolled hypertension and / or proteinuria. Patients must have
systolic blood pressure ≤ 150 mmHg and diastolic blood pressure ≤ 100 mmHg, and be on
stable blood pressure medication at the time of study entry. Patients discovered to
have ≥ 1+ proteinuria at baseline, should undergo a 24-hour urine collection and must
have < 500 mg of protein / 24 hours.

- History of allergic reactions, or intolerance, attributed to compounds of similar
chemical or biologic composition to 5-fluorouracil, irinotecan, or bevacizumab.

- Women who are pregnant or breastfeeding are excluded from this study because
bevacizumab is an antiangiogenic agent with the potential for teratogenic or
abortifacient effects. Because there is an unknown but potential risk for adverse
events in nursing infants secondary to treatment of the mother with bevacizumab,
breastfeeding should be discontinued if the mother is treated with bevacizumab.
These potential risks may also apply to other agents used in this study.

- Uncontrolled inter-current illness including, but not limited to, ongoing or active
infection, or psychiatric illness/social situations that would limit compliance with
study requirements.

- HIV-positive patients on combination antiretroviral therapy are ineligible because of
the potential for pharmacokinetic interactions with the agents used in this study.
In addition, these patients are at increased risk of lethal infections when treated
with marrow-suppressive therapy.

- Patients with active cardiovascular disease, i.e., unstable angina, New York Heart
Association grade II or greater congestive heart failure, serious cardiac arrhythmia
requiring medications, or grade II or greater peripheral vascular disease. In
addition, patients with arterial thrombosis, myocardial infarction, and cerebral
vascular accidents (stroke / transient ischemic attach (TIA)) within 6 months prior
to study entry will be excluded.

- Patients who had major surgical procedure, open biopsy or significant traumatic
injury within 28 days prior to the first study treatment, or anticipation of need for
major surgical procedure during the course of the study; minor surgical procedures
within 7 days prior to study treatment start.

- Planned radiotherapy for underlying disease.

- Serious non-healing wound or ulcer.

- Evidence of bleeding diathesis or coagulopathy.

- Current or recent (within 10 days prior to study treatment start) use of full dose
oral or intravenous anticoagulants or thrombolytic agents. Patients on low molecular
weight heparins are allowed to participate in the study. Patients with
anticoagulation for maintenance of patency of permanent indwelling intravenous
catheters will be eligible. However, INR should be monitored closely if patients are
taking low-dose coumadin for this purpose.

- Ongoing treatment with aspirin ( > 325 mg/day) or other medications known to
predispose to gastrointestinal ulceration.

- Patients who have received prior radiation therapy to > 15% of bone marrow (see
Appendix D), or standard pelvic radiation for rectal cancer.

- Patients with predisposing colonic or small bowel disorders in which symptoms are
uncontrolled as indicated by pre-treatment/baseline pattern of > 3 loose stools daily
in patients without a colostomy or ileostomy. Patients with a colostomy or ileostomy
may be entered as the investigator's discretion.

- Patients with partial or complete bowel obstruction, known chronic malabsorption,
total colectomy or other major abdominal surgery that might result in substantial
alteration in absorption of oral medications.

- Patients with known Gilbert's syndrome.

- Patients who were started on phenytoid, phenobarbital, carbamazepine or any other
enzyme-inducing anti-convulsant drug (EIACD) within 7 days prior to the first study
treatment or patients who are unable or unwilling to discontinue EIACD use or switch
to a non-EIACD at least 7 days prior to the first study treatment. Concomitant use
of gabapentin or other non-EIACDs is permitted.

- Patients who are unable or unwilling to discontinue St. John's wort (hypericum
perforatum) at least 14 days prior to the first study treatment; Patients who are
taking fluconazole / ketoconazole at the time of first study treatment.

- Lack of physical integrity of the upper gastrointestinal tract, malabsorption
syndrome, or inability to take oral medication.

- Organ allografts requiring immunosuppressive therapy.